Premium
Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma
Author(s) -
Cornelison Terri L.,
Goldberg Jeffrey M.,
Steven Piver M.
Publication year - 1995
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930590314
Subject(s) - medicine , chemotherapy , carcinoma , pancreatic cancer , pancreatic carcinoma , stage (stratigraphy) , gastroenterology , oncology , disease , pancreas , cancer , paleontology , biology
Pancreatic cancer and jejunal cancer are aggressive diseases with grim prognoses. The long term survival of pancreatic carcinoma is still one of the worst of all cancers. Ninety‐five percent of the patients die of their disease within 5 years [Wagener et al: Ann Oncol 5(Suppl 3): S87‐S90, 1994]. Eighty‐five percent of patients with jejunal carcinoma die of their disease within 5 years [Lioe, Biggart: J Clin Pathol 43: 533‐536, 1990]. To date, there are disappointingly few effective cytotoxic agents in the treatment of these cancers. We present a case of advanced‐stage pancreatic carcinoma and a case of advanced stage jejunal carcinoma, each showing marked response to Taxol and platinum chemotherapy.